Literature DB >> 8797698

Adult T-cell leukemia in Japan.

K Takatsuki1, M Matsuoka, K Yamaguchi.   

Abstract

Adult T-cell leukemia (ATL) was first reported in Japan, where it has a high incidence in the southwestern region. The retrovirus, human T-lymphotropic virus type I (HTLV-I), is found to be the causative agent of ATL. In ATL-endemic areas, the rate of HTLV-I carriers is high. A definite diagnosis of ATL is based on the presence of HTLV-I proviral DNA in the tumor cell DNA. ATL cells originate from the CD4 subset of peripheral T cells. ATL shows diverse clinical features but can be divided into four subtypes: the acute, chronic, smoldering, and lymphoma types. Chemotherapy is not effective; the acute and lymphoma types have a poor prognosis. Familial occurrence of ATL is common. HTLV-I infection is caused by transmission of live infected lymphocytes from mother to child, or from man to woman, or by blood transfusion.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8797698     DOI: 10.1097/00042560-199600001-00004

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr Hum Retrovirol        ISSN: 1077-9450


  3 in total

1.  Clinical and oncologic implications in epigenetic down-regulation of CD26/dipeptidyl peptidase IV in adult T-cell leukemia cells.

Authors:  Tomohiro Tsuji; Kazuyuki Sugahara; Kazuto Tsuruda; Akiko Uemura; Hitomi Harasawa; Hiroo Hasegawa; Yukio Hamaguchi; Masao Tomonaga; Yasuaki Yamada; Shimeru Kamihira
Journal:  Int J Hematol       Date:  2004-10       Impact factor: 2.490

2.  Prevalence of Human T-lymphotropic virus type 1 and 2 among blood donors in Manaus, Amazonas State, Brazil.

Authors:  Márcia Poinho EncarnaçÃo de Morais; Cynara Melo Gato; Lucinei Alves Maciel; Pritesh Lalwani; Cristóvão Alves Costa; Jaila Dias Borges Lalwani
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2017-12-21       Impact factor: 1.846

Review 3.  Human T-cell lymphotropic-I-associated leukemia/lymphoma.

Authors:  R S Siegel; R B Gartenhaus; T M Kuzel
Journal:  Curr Treat Options Oncol       Date:  2001-08
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.